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Abstract: There is an implied assumption that addictions to different substances vary in 
strength from weak (easier to stop) to strong (harder to stop), though explicit definitions 
are lacking. Our hypothesis is that the strength of addictions can be measured by cessation 
rates found with placebo or no treatment controls, and that a weaker addiction would have 
a higher cessation rate than a stronger addiction. We report an overview of systematic 
reviews and meta-analyses of cessation trials, using randomised or quasi-randomised trials 
and reporting objectively-measured abstinence. The outcome for comparison was quit   
rates–typically the percentage of participants abstinent according to an objective test of 
abstinence at six months or longer. Twenty-eight cessation reviews (139,000 participants) 
were found. Most data came from reviews of smoking cessation in over 127,000 participants, 
and other reviews each covered a few thousand participants. Few reviews used data from 
studies shorter than three months, and almost all determined abstinence using objective 
measures. Cessation rates with placebo in randomised trials using objective measures of 
abstinence and typically over six months duration were 8% for nicotine, 18% for alcohol, 
47% for cocaine, and 44% for opioids. Evidence from placebo cessation rates indicates that 
nicotine is more difficult to give up than alcohol, cocaine, and opioids. Tobacco is also a 
severe addiction, with a number of major deleterious health effects in a large number  
of people. 
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1. Introduction 
A recent review considering the definition of addiction highlighted five essential elements, which 
mainly  addressed  issues of the individuals  and their behaviour and interaction with addictive  
stimuli [1]. Addictive interactions also involve the addictive stimulus itself, and the interactions are 
often described as strong or severe, without clear explanation of what strong or severe means. Here we 
hypothesis that it may be possible to assess the strength of an addiction in terms of how hard it is to 
break, and the severity of an addiction in terms of adverse physical, psychological and social effects, 
the duration of the addiction, and the number of people affected. It should be emphasised that a 
dictionary definition of hypothesis is “a supposition or proposed explanation made on the basis of 
limited evidence as a starting point for further investigation”; that is exactly the case here, where there 
is no significant prior evidence, merely an assumption that this might be reasonable. 
There is an implied assumption that addictions to different substances vary in strength from weak 
(easier to stop) to strong (harder to stop), though explicit definitions are lacking. Using the data of the 
National Epidemiologic Survey on Alcohol and Related Condition, Lopez-Quintero et al. have shown 
that the probability of a transition from first use to dependence was greater with nicotine followed by 
alcohol, cocaine, and cannabis [1], and that after the onset of dependence, remission appeared usually 
first for cocaine, followed by cannabis, alcohol, and finally nicotine [2]. Another way to explore the 
strength of addictions is to measure cessation rates found with placebo or no treatment controls; a 
weaker addiction would have a higher cessation rate than a stronger addiction. 
Comparing different forms of addiction in order to categorise the strength of addiction is not easy 
for reasons concerning participants, setting, and details of study design: 
1.  Motivation to quit and the anticipated benefit are predictors of substance cessation [3], and 
treatment intensity affects outcome, as shown in smoking cessation meta-analysis [4]. These 
can be linked and differ markedly between addictions. Alcohol dependent subjects entering 
treatment with current social and psychological distress that improves dramatically in days or 
weeks of inpatient treatment are quite different from smokers with no apparent immediate 
benefit trying to quit alone and at home. 
2.  Individual circumstances differ. An example might be individuals recruited in primary care for 
a short intervention for smoking cessation, compared to those in hospital with a recent 
diagnosis of smoking-related disease [5]. Recent smoking cessation trials have shown quit rates 
to be better after admission for coronary heart disease [6,7]. 
3.  Types and intensity of intervention may be an influence, divided mainly between psychosocial 
interventions (cognitive behavioural, support psychotherapy) and drugs of various sorts. 
4.  Cessation can be defined in a number of ways. Best is to have some objective test, like breath 
carbon monoxide or urine cotinine for nicotine, benzoylecgonine or opioid metabolites for 
illicit drugs, and biochemical tests for alcohol. Self-reported abstinence is likely to be less 
reliable, unless confirmed by a significant other. Int. J. Environ. Res. Public Health 2012, 9  194 
 
 
5.  Duration of observation is likely to be an issue. Many smokers have given up for a day; few 
give up for a month, and only a small percentage for a year or more. Comparing studies of 
different duration may be problematical. 
6.  Issues around size. Many studies in addiction are quite small, with a few tens of participants. We 
know that small studies are problematic, and that the random play of chance can have a major 
influence on results [8] such that results with fewer than 200 actual events may mislead [9]. 
The best source of information will be from published systematic reviews and meta-analyses of 
randomised trials of interventions to improve quit rates with information after defined periods (six months, 
12 months, longest), and in which placebo or no-treatment controls are a common comparator.  
2. Methods 
Systematic reviews and meta-analyses were sought of interventions to increase quit rates. Two 
main searching strategies were employed: 
1.  Searching of Cochrane Library for Cochrane reviews, using key words tobacco, nicotine, 
alcohol, drinking, cocaine, heroin, opioids, and by examining lists of reviews from the 
appropriate review groups. 
2.  Searching PubMed, using similar key words in title or abstract, in humans, and in English. 
Related article links were also used. 
Only systematic reviews or meta-analyses were used. Where several examined the same subject, the 
most recent and largest was chosen. Analyses of predominantly short-term outcomes were excluded 
because these may not provide a reliable measure of longer-term abstinence. In general, articles with 
cessation rates after at least six months were chosen; some included a few studies with shorter duration 
(three  months, for example), but the proportion of short duration studies was small. Those using 
randomised or quasi-randomised trials were preferred; in some conditions where there was limited 
evidence from randomised trials, some controlled trials that were not convincingly randomised had 
been included in the reviews, but the amount of information from this source was a small minority of 
the total available. These few reviews were included to provide information where otherwise none 
would have been available; this was mostly in interventions for cocaine abuse, where the number of 
subjects for any review was small. For example, non-randomised studies contributed fewer than 1% of 
patients in reviews of smoking cessation. 
The outcome for cessation trials was quit rates–typically the percentage of participants abstinent 
according to an objective test of abstinence at six months or longer. Results from each review are 
presented as absolute quit rates with treatment and placebo, together with a relative benefit or risk, and 
number needed to treat (NNT). We abstracted cessation rates for individual trials included in the 
reviews, and calculated overall cessation rates for intervention and placebo. For completeness, and to 
demonstrate that studies measuring placebo responses were sensitive in that interventions caused 
change in response, we also calculated relative risk with 95% confidence interval (CI) using the fixed 
effects models [10]; statistical significance was assumed when the 95% CI did not include one. 
Numbers needed to treat (NNT) compared with placebo with 95% confidence interval were calculated 
from pooled data [11] only with a statistically significant results.  Int. J. Environ. Res. Public Health 2012, 9  195 
 
 
3. Results 
Table 1 contains details of and references to 12 systematic reviews for tobacco cessation studies, 
three for alcohol, seven for cocaine, and five for opioids. Another meta-analysis of psychosocial 
interventions reported results for polysubstance use, cocaine, opioids, and cannabis [12]. In total,  
the 28 reviews reported on almost 139,000 participants.  
3.1. Nicotine 
Information was available from 12 systematic reviews [13-24], 11 of which were Cochrane 
reviews, covering drug interventions and interventions including behavioural counselling, group 
therapy, and exercise programmes, as well as nurse or doctor interventions. Data were available on 
over 127,000 participants with cessation rates at six months or longer, with the bulk from reviews of 
nicotine replacement therapy (NRT), physical intervention, self-help, nursing interventions and 
bupropion. Most reviews used only properly randomised trials (one used controlled trials), used 
objective means to assess abstinence, and used either placebo or, in the case of behavioural 
interventions, used an appropriate control like a minimal intervention or brief advice.  
Table 2 shows the main results in terms of percentage of abstinent participants with intervention 
and placebo or control. There was a consistent response for placebo, of between 3% and 14%, with an 
overall average cessation rate of 8.4% in 57,867 participants on placebo. There appeared to be a lower 
cessation rate of 6.7% in 30,837 participants with placebo or minimal interventions in behavioural 
interventions, compared with 10.3% in 27,640 participants for placebo in drug interventions. This may 
reflect differences in populations studied or differences in methods, like blinding differences. Most 
interventions were effective to some extent, with NNTs varying between 7 (95% CI 6 to 10) for 
varenicline to 65 (45 to 110) for self-help. 
The very large numbers of participants in nicotine replacement therapy (NRT) studies [22] allowed 
investigation of a number of variables that might affect the results obtained with placebo. The first  
was size.  
Figure 1 demonstrates a consistent cessation rate with placebo below 20%, and predominantly 
below 10% with group sizes of 300 participants and above. It also shows very variable cessation rates 
of a few percent to almost 50% where group size was 100 or below. Figure 2 shows the cessation rates 
with placebo or control in nicotine, alcohol, cocaine and opiates. 
Table 3 examines other possible influences. Neither type of NRT product (gum, patch, inhaler, 
lozenge, or spray) nor duration of follow up beyond six months made any difference to placebo 
cessation rates. Participants from smoking clinics, and those with a high level of support in a group 
setting achieved somewhat higher rates of cessation, though below 20%. Twelve month studies were 
less effective (NNT 21; 95% CI 18 to 25) than sixth month studies (NNT 9.4; 7.9 to 12). 
This very large body of data, from many different interventions conducted in a variety of settings, 
shows that with placebo or no treatment after six months or longer the overall quit rate for smoking 
cessation is low, at about 10%. The information allows the conclusion that small studies can give 
highly variable and misleading results, especially where the group size is below 200 participants. Int. J. Environ. Res. Public Health 2012, 9  196 
 
Table 1. Details of included reviews. 
1. Tobacco smoking cessation reviews 
Reference  Interventions  Study characteristics  Duration  Outcome 
Abstinence with 
Comments 
Intervention  Placebo 
Cahill and Ussher 
2007 [13] 
Rimonabant 
(cannabinoid 
receptor antagonists) 
and placebo for 
tobacco cessation 
RCTs in adult smokers 
Lost to follow up 
regarded as continuing 
smokers 
Prolonged abstinence 
defined biochemically at 
each study visit 
At least  
6 months 
Smoking status at 
minimum of  
1 year 
Prolonged abstinence 
R 20 mg week 50: 
87/528 (16.4%) 
Prolonged abstinence 
R 5 mg week 50: 
63/518 (11%) 
Prolonged 
abstinence week 
50: 57/521 (11%) 
RR 1.5  
(1.1 to 2.1) 
for 20 mg 
Gourlay et al.  
2004 [14] 
Clonidine and 
placebo for tobacco 
cessation 
RCTs in adult smokers 
Control (placebo) 
usually involved some 
form of behavioural 
therapy. 
4.5 months to 
1 year 
Smoking status 
by a variety of 
methods, 
including self 
report 
Smoking cessation at 
longest time: 98/393 
(25%) 
Smoking cessation 
at longest time: 
55/383 (14.4%) 
RR 1.6  
(1.2 to 2.2) 
Hughes et al.  
2007 [16] 
Antidepressants and 
placebo for smoking 
cessation 
RCTs in adult smokers 
Control (placbeo) 
sometimes used 
behavioural therapy or 
similar interventions 
At least  
6 months 
from start of 
intervention 
Abstinence from 
smoking, 
assessed at 
follow up by 
various means 
Nortriptyline  
Smoking cessation at 
6 months or longer: 
100/480 (20.8%) 
 
 
Bupropion 
Smoking cessation at 
6 months or longer: 
1,056/5,557 (19%) 
Placebo 
Smoking cessation 
at 6 months or 
longer: 49/495 
(9.9%) 
 
Bupropion 
Smoking cessation 
at 6 months or 
longer: 417/4383 
(9.5%) 
RR 2.0  
(1.5 to 2.8) 
 
 
 
 
RR 1.8  
(1.6 to 1.9) 
(data here for 
clinical 
setting, 6 and 
12 months 
follow up, 
type of 
patient) Int. J. Environ. Res. Public Health 2012, 9  197 
 
 
Table 1. Cont. 
Reference  Interventions  Study characteristics  Duration  Outcome 
Abstinence with 
Comments 
Intervention  Placebo 
Cahill et al.  
2007 [15] 
Nicotine receptor 
partial agonists and 
placebo for smoking 
cessation 
RCTs in adult smokers 
Lost to follow up 
regarded as continuing 
smokers 
Control (placebo) 
usually involved some 
form of behavioural 
therapy. 
Minimum 
follow up of 
at least 6 
months 
Abstinence from 
smoking, 
assessed at 
follow up by 
various means 
Varenecline 2 mg 
Smoking cessation at 
6 months or longer: 
232/1,082 (21.4%) 
Placebo 
Smoking cessation 
at 6 months or 
longer: 75/941 
(8.0%) 
RR 2.7  
(2.1 to 3.5) 
Stead et al.  
2008 [22] 
Nicotine 
replacement therapy 
and placebo for 
smoking cessation 
RCTs in adult smokers 
Lost to follow up 
regarded as continuing 
smokers 
Control (placebo) 
usually involved some 
form of behavioural 
therapy. 
Minimum 
follow up of 
at least  
6 months 
Abstinence from 
smoking, 
assessed at 
follow up by 
various means 
All NRT/doses 
Smoking cessation at 
6 months or longer: 
3,822/22,711 (16.8%) 
All NRT/doses 
Smoking cessation 
at 6 months or 
longer: 
2,115/20,307 
(10.4%) 
RR 1.6  
(1.5 to 1.7) 
Placebo 
results 
virtually 
identical for 
all modes of 
delivery of 
NRT 
Lancaster and 
Stead 2005 [17] 
Individual 
behavioural 
counseling 
Not all were properly 
randomised trials (but 
these were a minority of 
the trials included, most 
of which were properly 
randomised), and with 
versus no treatment, 
brief advice or self-help 
materials as the control 
Minimum 
follow up of 
at least  
6 months 
Abstinence from 
smoking, 
assessed at 
follow up by 
various means 
Behavioural therapy 
Smoking cessation at 
6 months or longer: 
291/2,513 (11.6%) 
Control 
Smoking cessation 
at 6 months or 
longer: 195/2,515 
(7.8%) 
RR 1.5  
(1.3 to 1.8) Int. J. Environ. Res. Public Health 2012, 9  198 
 
 
Table 1. Cont. 
Reference  Interventions  Study characteristics  Duration  Outcome 
Abstinence with 
Comments 
Intervention  Placebo 
Ussher 2005 [23]  Supervised or 
unsupervised 
exercise 
programmes 
RCTs in smokers 
wishing to quit or recent 
quitters 
Minimum  
6 months 
Abstinence from 
smoking 
Exercise 
Smoking cessation at 
6 months or longer: 
113/635 (18%) 
Control 
Smoking cessation 
at 6 months or 
longer: 83/610 
(14%) 
RR 1.2 
(0.9 to 1.5) 
Stead and 
Lancaster  
2005 [21] 
Group therapy 
versus individual 
self help 
RCTs  Minimum  
6 months 
Abstinence from 
smoking by 
measurement 
Group 
Smoking cessation at 
6 months or longer: 
249/2,388 (10%) 
Control 
Smoking cessation 
at 6 months or 
longer: 116/2,007 
(5.8) 
RR 1.9 
(1.5 to 2.3) 
Rice and Stead 
2008 [19] 
Nursing intervention  RCTs  Minimum  
6 months 
Abstinence from 
smoking by 
measurement 
Nursing 
Smoking cessation at 
6 months or longer: 
1,154/8,383 (14%) 
Control 
Smoking cessation 
at 6 months or 
longer: 761/6,822 
(11%) 
 
Stead et al.  
2008 [20] 
Physician 
intervention 
RCTs  Minimum  
6 months 
Abstinence from 
smoking by 
measurement 
PhysicianSmoking 
cessation at 6 months 
or longer: 
1,029/12,584 (8.2%) 
ControlSmoking 
cessation at  
6 months or longer: 
470/9,676 (4.9%) 
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Table 1. Cont. 
2. Alcohol cessation reviews   
Reference  Interventions  Study characteristics  Duration  Outcome 
Abstinence with 
Comments 
Intervention  Placebo 
Srisurapanont and 
Jarusuraisin  
2005 [25] 
Opioid antagonists 
or placebo 
RCTs only 
Participants with 
alcohol dependence 
established by any 
criteria 
Various 
durations, up 
to 3 months, 
more than  
3 months, 
longer than  
12 months 
Number not 
returned to any 
drinking, or 
heavy drinking 
Short term: 
Heavy drinking or 
relapse 300/415 
(72%) 
Any drinking 220/517 
(43%) 
 
Medium term: 
Heavy drinking or 
relapse 56/107 (52%) 
Any drinking 9/40 
(23%) 
Short term: 
Heavy drinking or 
relapse 234/407 
(57%) 
Any drinking 
172/497 (35%) 
 
Medium term: 
Heavy drinking or 
relapse 37/101 
(37%) 
Any drinking 6/40 
(15%) 
Results 
converted to 
quit rates 
Very low 
quit rates in 
small study 
longer than  
1 year 
Srisurapanont and 
Jarusuraisin  
2004 [25] 
Acamprosate or 
placebo 
RCTs only 
Standard definition of 
alcoholism 
Usually with some form 
of psychosocial 
intervention 
Duration 2 to 
24 months 
Abstinence rate  417/1,775 (24%)  231/1,549 (14.9%)  1.6 
(1.4 to 1.9) 
Bouza et al.  
2004 [26] 
Naltrexone or 
placebo 
RCTs only 
Standard definition of 
alcoholism 
Usually with some form 
of psychosocial 
intervention 
Duration 2 to 
24 months 
Abstinence rate  190/544 (35%)  160/533 (30%)  1.2 
(0.98 to 1.4) Int. J. Environ. Res. Public Health 2012, 9  200 
 
 
Table 1. Cont. 
3. Cocaine cessation reviews   
Reference  Interventions  Study characteristics  Duration  Outcome 
Abstinence with 
Comments 
Intervention  Placebo 
Minozzi et al.  
2008 [27] 
Anticonvulsants and 
placebo 
Randomised trials and 
controlled trials 
Cocaine dependent 
patients (DSM 
classification) 
Adults 
Mean 
duration  
11 weeks 
(range 1–24 
weeks) 
Non-use of 
cocaine (self 
report or 
measurement) 
126/270 (47%)  102/198 (52%)  RR 1.1 
(0.9 to 1.3) 
Lima Reisser et al. 
2002 [28] 
Carbamazepine and 
placebo 
Randomised trials  
Cocaine dependent 
patients (DSM 
classification) 
Adults 
1–6 months  Maintained in the 
programme—did 
not drop out 
60/152 (39.5%)  51/161 (31.7%)   
Silva de Lima et al. 
2003 [29] 
Antidepressants and 
placebo 
 
results for 
desipramine 
Randomised trials and 
controlled trials 
Cocaine dependent 
patients (DSM 
classification) 
Adults 
1–6 months  Non-use of 
cocaine 
(measurement) 
59/136 (43.3%)  65/130 (50%)   
Soares et al.  
2003 [30] 
Dopamine agonists 
and placebo 
 
results for 
amantadine 
Randomised trials  
Cocaine dependent 
patients (DSM 
classification) 
Adults 
2–16 weeks+, 
but mainly 
12–16 weeks 
Non-use of 
cocaine 
(measurement) 
34/88 (38.6%)  34/127 (26.8%)   
Amato et al.  
2007 [31] 
Antipsychotics and 
placebo 
Randomised trials and 
controlled trials 
Cocaine dependent 
patients (DSM 
classification) 
Adults 
6–24 weeks  Maintained in the 
programme—did 
not drop out 
62/106 (58%)  46/102 (45%)   Int. J. Environ. Res. Public Health 2012, 9  201 
 
 
Table 1. Cont. 
Reference  Interventions  Study characteristics  Duration  Outcome 
Abstinence with 
Comments 
Intervention  Placebo 
Knapp et al.  
2007 [32] 
Cognitive 
behavioural therapy 
versus counseling 
Randomised trials  
Cocaine dependent 
patients (DSM 
classification) 
Adults 
4–6 months  Maintained in the 
programme—did 
not drop out 
157/289 (54%)  130/281 (46%)   
Castells et al.  
2007 [33] 
Mandizol, 
dexamphetamine, 
methylphenidate, 
modafinil, 
buproprion and 
placebo 
Randomised trials 
Cocaine dependent 
patients (DSM 
classification)Adults 
1–6 months  Maintained in the 
programme—did 
not drop out 
177/344 (51%)  158/296 (53%)    
4. Opioids cessation reviews   
Reference  Interventions  Study characteristics  Duration  Outcome 
Abstinence with 
Comments 
Intervention  Placebo 
Amato et al.  
2004 [34] 
Psychosocial and 
pharmacological 
treatments versus 
pharmacological 
treatments 
RCTs  Mostly of  
6 months or 
more 
Number opioid 
free at end of 
treatment 
Psych + Pharm 
Opioid free at about  
6 months: 37/89 
(42%) 
Pharm only 
Opioid free at 
about 6 months: 
24/95 (25%) 
 
Farré et al.  
2002 [35] 
Methadone, 
buprenorphine, 
placebo 
RCT 
Methadone maintenance 
at least 12 weeks 
Various measures of 
retention or illicit drug 
use 
Studies 13–40 
weeks, mostly 
6 months or 
more 
Freedom from 
illicit drug use 
Methadone: 
481/1,004 (52%) 
Buprenorphine: 
164/275 (40%) 
Placebo: 
65/131 (50%) 
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Table 1. Cont. 
Reference  Interventions  Study characteristics  Duration  Outcome 
Abstinence with 
Comments 
Intervention  Placebo 
Mattick et al.  
2003 [36] 
Methadone 
maintenance versus 
tapering 
RCTs  Various 
times, largely 
of the order of  
6 months 
Retained in 
treatment 
Drug free urine 
Methadone 
maintenance: 
Retained 173/254 
(68%) 
DFU: 103/195 (53%) 
Tapered 
Retained: 63/251 
(25%) 
DFU: 49/214 
(23%) 
 
Mattick et al.  
2008 [37] 
Buprenorphine or 
placebo 
RCTs  Shortest  
4 week, 
others  
2 months or 
longer 
Retained in 
treatment opioid 
free 
Buprenorphine 
Opioid free: 495/742 
(67%) 
Placebo 
Opioid free: 
202/476 (42%)   
Gowing et al.  
2006 [38] 
buprenorphine, 
clonidine, other 
active, but not 
placebo 
RCTs or quasi 
randomised trials 
Mostly short 
term 
Number 
completing 
programme, 
presumably drug 
free, but that is 
not explicitly 
stated 
Buprenorphine 
317/506 (63%) 
Clonidine 
155/378 (41%) 
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Table 2. Results of smoking cessation reviews, ordered by number of participants. The 
order is by numbers of participants in the reviews. Intervention is as described in each 
review, and details of the reviews is in Table 1.  
Intervention 
(trial six months or 
longer) 
Numbers of 
patients 
Percent abstinent with  Relative 
benefit  
(95% CI) 
NNT  
(95% CI)  Active  Placebo 
Nicotine 
replacements 
therapy 
43,108  17  10  1.6 (1.5 to 1.7)  16 (14 to 17) 
Physician 
intervention 
22,260  8  5  1.8 (1.6 to 2.0)  30 (25 to 37) 
Self help  19,504  7  5  1.3 (1.2 to 1.5)  65 (45 to 110) 
Nursing intervention  15,205  14  11  1.4 (1.3 to 1.5)  38 (27 to 64) 
Bupropion  9,940  19  10  2.0 (1.8 to 2.2)  11 (9 to 12) 
Counselling  5,028  12  8  1.5 (1.3 to 1.8)  26 (18 to 46) 
Group therapy  
(versus self help) 
4,395  10  6  1.9 (1.5 to 2.3)  22 (16 to 33) 
Varenecline  2,023  21  8  2.7 (2.1 to 3.4)  7 (6 to 10) 
Cut down to quit 
with NRT 
1,833  7  3  2.0 (1.3 to 3.0)  30 (19 to 74) 
Exercise  1,245  18  14  1.2 (0.9 to 1.5)  24 (12 to 640) 
Rimonabant  1,049  17  11  1.5 (1.1 to 2.1)  18 (10 to 72) 
Notriptyline  975  21  10  2.1 (1.5 to 2.9)  9 (6 to 16) 
Clonidine  776  25  14  1.7 (1.3 to 2.4)  9 (6 to 20) 
Figure 1.  Cessation (quit) rates with placebo in NRT studies according to number in 
placebo group (size of symbol proportional to number in placebo group, inset scale) (data 
from Stead et al., 2008 [22]). 
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Figure 2. Cessation rates with placebo across different addictions (number of participants). 
 
Table 3. Influence of variables in NRT trials on cessation rates with placebo. Intervention 
is as described in each review, and details of the reviews is in Table 1.  
Variable 
Numbers 
of patients 
Percent abstinent with  Relative benefit  
(95% CI) 
NNT  
(95% CI)  NRT  Placebo 
All trials six months or longer  43,108  17  10  1.6 (1.5 to 1.7)  16 (14 to 17) 
Duration of follow up           
Six months  4,480  20  9  1.9 (1.6 to 2.2)  9.4 (7.9 to 12) 
Twelve months  24,520  15  10  1.5 (1.4 to 1.6)  21 (18 to 25) 
Trial setting           
Community volunteers  18,823  20  14  1.5 (1.4 to 1.7)  17 (14 to 20) 
Smoking clinic  1,283  30  19  1.6 (1.3 to 1.9)  9 (7 to 17) 
Primary care  11,427  11  7  1.5 (1.3 to 1.7)  25 (20 to 34) 
Hospital recruitment  3,236  14  10  1.3 (1.04 to 1.6)  25 (16 to 62) 
Level and type of support           
Low level of support  12,348  13  8  1.6 (1.4 to 1.7)  20 (16 to 25) 
High level support for individual  16,907  15  10  1.5 (1.4 to 1.6)  21 (17 to 26) 
High level support for group  7,140  27  18  1.6 (1.4 to 1.7)  11 (9 to 14) 
Type of NRT           
Gum  19,120  18  11  1.4 (1.3 to 1.5)  15 (13 to 17) 
Patch  18,175  16  10  1.7 (1.5 to 1.8)  17 (15 to 20) 
Inhaler  986  17  9  1.9 (1.3 to 2.6)  13 (8 to 28) 
Lozenge or tablet  3,109  16  8  2.0 (1.6 to 2.5)  12 (10 to 17) 
Nasal spray  887  24  12  2.0 (1.5 to 2.7)  8 (6 to 14) 
3.2. Alcohol 
Information was available from two systematic reviews [25,26] with data on over 4,600 participants 
(predominantly acamprosate and naltrexone [26]) were used, with cessation rates between three and 12 
or 24 months; one review of opioid antagonists had 208 participants in longer-term studies [25]. Both 
used only properly randomised trials, used various means to assess abstinence, and used placebo, 
usually with some form of psychosocial intervention. Int. J. Environ. Res. Public Health 2012, 9  205 
 
 
Table 4 shows the main results in terms percentage of abstinent participants with intervention and 
placebo. The quit rate with placebo in the two larger reviews was 15% and 30%, with an overall 
average cessation rate of 18% in 2,082 participants on placebo. Only acamprosate had sufficient 
information to demonstrate effectiveness, with an NNT of 12 (95% CI 9 to 17). 
Table 4. Results of alcohol cessation reviews, ordered by number of participants. The 
order is by numbers of participants in the reviews. Intervention is as described in each 
review, and details of the reviews is in Table 1.  
Intervention 
Number of 
patients 
Percent abstinent with  Relative benefit 
(95% CI) 
NNT  
(95% CI)  Active  Placebo 
Acamprosate  3,324  23  15  1.6 (1.4 to 1.8)  12 (9 to 17) 
Naltrexone  1,077  35  30  1.2 (1.0 to 1.4)  not calculated 
Opioid antagonists  208  52  37  1.4 (1.0 to 2.0)  6 (3 to 43) 
3.3. Cocaine 
Information was available from seven systematic reviews [27-33], six of which were Cochrane 
reviews. Six reviews examined drug therapies, and one cognitive behavioural therapy. 
There was data on over 2,600 participants with cessation rates ranging between one and six months, 
though most comparisons were relatively small in size. All used only properly randomised trials in 
participants with defined cocaine addiction, used a mixture of non-use of cocaine by measurement or 
retention in a programme to assess abstinence, and used placebo or counselling. Studies using 
validated non-use by measurement or maintenance in programme appeared not to differ in cessation 
rates with placebo. 
Table 5. Results of cocaine cessation reviews, ordered by number of participants. The 
order is by numbers of participants in the reviews. Intervention is as described in each 
review, and details of the reviews is in Table 1. 
Intervention 
Number 
of patients 
Percent abstinent with  Relative benefit  
(95% CI) 
NNT  
(95% CI)  Active  Placebo 
CNS stimulants  640  51  53  1.0 (0.8 to 1.1)  not calculated 
Cognitive 
behavioural therapy 
570  54  46  1.2 (1.0 to 1.4)  not calculated 
Anticonvulsants  468  47  52  0.9 (0.8 to 1.1)  not calculated 
Carbamazepine  313  39  32  1.3 (0.9 to 1.7)  not calculated 
Desipramine  266  43  50  0.9 (0.7 to 1.1)  not calculated 
Amantadine  215  39  27  1.4 (1.0 to 2.1)  not calculated 
Antipsychotics  208  58  45  1.3 (1.0 to 1.7)  not calculated 
Table 5 shows the main results in terms percentage of abstinent participants with intervention and 
placebo, and the relative benefit. The quit rate with placebo varied between 27% and 53%, with an 
overall average cessation rate of 47% in 1,134 participants  on placebo (not double counting 
carbamazepine results with those of anticonvulsants). A review of psychosocial interventions had a Int. J. Environ. Res. Public Health 2012, 9  206 
 
 
placebo quit rate of 21% in a small number of small trials [12]. No intervention was significantly 
better than placebo. 
3.4. Opioids 
Information was available from five systematic reviews [34-38], four of which were Cochrane 
reviews. Three reviews included data of six months or longer, and two [37,38] of one to six months. 
There were a variety of interventions, including psychosocial and pharmacological, mainly methadone 
or buprenorphine. The reviews mainly used only properly randomised trials in participants with 
defined opioid addiction, used a mixture of non-use of opioid by measurement or retention in a 
programme to assess abstinence, and used placebo, or, in one review, maintenance methadone versus 
tapered withdrawal. There was information on over 2,300 participants with cessation rates over   
various times. 
Table 6 shows the main results in terms percentage of abstinent participants with intervention and 
placebo. For methadone, results are taken from a review [35]  reporting true placebo and not 
contaminated with tapering methadone dose. For psychosocial plus pharmacological interventions, the 
placebo response included pharmacological interventions and may not be a true placebo, and some of 
the buprenorphine trials used clonidine as a control. The quit rate with placebo varied between 25% 
and 50%, with an overall average cessation rate of 43% in 590  participants on true  placebo  in 
methadone and buprenorphine trials. A review of psychosocial interventions had a placebo quit rate of 
24% in a small number of small trials [12]. Only buprenorphine showed any efficacy in a sensible 
number of patients, with an NNT of 4.6 (95% CI 3.6 to 6.6). 
Table 6. Results of opioid cessation reviews, ordered by number of participants. The order 
is by numbers of participants in the reviews. Intervention is as described in each review, 
and details of the reviews is in Table 1.  
Intervention 
Number of 
patients 
Percent abstinent with  Relative benefit 
(95% CI) 
NNT  
(95% CI)  Active  Placebo 
Methadone  1,135  48  50  1.0 (0.8 to 1.7)  not calculated 
Buprenorphine  884  63  41  1.7 (1.5 to 2.0)  4.6 (3.6 to 6.6) 
Psychosocial plus 
pharmacological 
184  42  25  1.7 (1.1 to 2.6)  6.1 (3.4 to 35) 
3.5. Cannabis 
The abstinence rate in a single review [12] of mostly short term psychotherapeutic interventions for 
cannabis dependence was 15% in a small number of small trials. 
4. Discussion 
Cessation rates with true placebo in randomised trials using objective measures of abstinence and 
typically over six months duration were 8% for nicotine, 18% for alcohol, 47% for cocaine, and 43% 
for opioids. This overview of systematic reviews sought evidence of different quit rates with placebo Int. J. Environ. Res. Public Health 2012, 9  207 
 
 
in addictions to different substances, and apparently found it. Before accepting such a result at face 
value, it is necessary to explore how robust it is. 
By concentrating on data from systematic reviews and meta-analyses of randomised trials reporting 
abstinence at six months or longer it relied on studies least open to bias. Most information came from 
reviews of smoking cessation in over 127,000 participants, though reviews for treatments of other 
addictions covered a few thousand participants. Most of the reviews included had a preponderance of 
longer-term studies, with determination of abstinence using objective measures. As much as possible, 
therefore, comparisons were of like for like. 
The example of nicotine replacement therapy, with over 43,000 participants in trials of six months 
or longer, showed that vagaries of trial design made little difference to placebo response rates, though 
trials lasting 12 months were less effective than those lasting only six months. Together, these 
approaches support the contention that between-addiction comparisons of quit rates with placebo   
are justified. 
Unresolved issues include how missing data are treated in clinical trials; missing data should 
probably be counted as failure, but this may not be uniformly applied, and is not generally discussed. 
Trials with cocaine addicts had shorter durations than with other substances. As the abstinence rate 
tends to decrease with time, this bias is of concern. 
The use of a no-treatment control rather than actual placebo might be important in both non-drug 
and drug interventions. Placebo has been shown to produce genuine effects through psychological 
mechanism (involving expectations, conditioning learning, memory, motivation somatic focus, reward, 
anxiety reduction, and meaning), as well as changes of metabolic activity in different brain regions in 
cocaine  abusers  [39]. Context effects could also be a source of variation in placebo response   
rates [40,41]. However, placebo response rates tend to be consistent in particular randomised trial 
models, using the same outcomes, over the same period of time [42], differing only when the outcome 
differs [43-45]. In the case of addiction, the same outcome was being sought over the same time.  
We have shown a high variability of success rates in smoking cessation trials where the group size 
is below 200 subjects. Trials with fewer than 200 participants were over-represented in opiate and 
cocaine studies. 
Finally, studies included in the systematic reviews were sensitive in that interventions caused 
change in response, with statistically significant relative benefit. This should give comfort that placebo 
response measured were meaningful. Few interventions were shown to be highly effective, and low 
NNTs were rare, except for buprenorphine treatment for opioid addiction, where one opioid replaces 
another (Table 5). 
The conclusion, then, is that in the circumstances chosen, placebo quit rates are a useful proxy 
marker for the strength of different addictions. The results point to tobacco being by far the strongest, 
as has already suggested the findings from epidemiological data [1,2]. 
Tobacco addiction is far more widespread than other addictions. Many smokers are not alcohol or 
drug addicts, though most alcohol or drug addicts are also smokers. One can hypothesize on individual 
vulnerability to addictive behaviours, this vulnerability being highest in alcohol and drug addicts. One 
other approach could be to look at differential outcomes in tobacco and other substance cessation  
in subjects having a dual addiction. In this respect, it has been shown that alcohol outcome was far 
better than tobacco outcome in alcoholic smokers undergoing an alcohol and tobacco concurrent Int. J. Environ. Res. Public Health 2012, 9  208 
 
 
intervention [46]. Everyday practice shows that many alcoholics consider that quitting tobacco to be 
far more difficult to quit than alcohol. Likewise, polydrug abusers often consider that tobacco would 
be the last substance they would be able to quit. 
It is also the case that, of all abused substances, nicotine is the one where the risk of developing a 
dependence syndrome is the highest after first exposure [1,47,48]. Even this leaves us problems, as the 
authors themselves use conflicting language [47]: “Over 80% of those who had used tobacco six or 
more times met dependence criteria…It appears that tobacco readily produces dependence (perhaps 
more so than most other substances), yet it does not progress to severe levels of dependence as readily 
as cocaine, heroin and most other drugs. Though it easily causes compulsive use, tolerance, and 
withdrawal, tobacco may be less likely to get “out of control” and progress to severe dependence than 
most other drugs”. 
Perhaps the biggest difficult is that, with addiction, there are several dimensions. These include the 
swiftness with which an addiction takes hold, the severity or otherwise of deleterious effects, the time 
course of their development, whether they are balanced by any possible beneficial effects, how many 
are affected, and how easy it is for an addiction to be broken. In all of these dimensions, tobacco 
addiction rates high. It is a strong addiction, being of rapid onset and hard to break, as evidenced by 
the large amount of good quality evidence of low placebo response rates in cessation trials, and of 
major public health concern because of its negative effects on health in a large number of people. 
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